Phages are particularly advantageous anti-infectives as they are novel therapeutics, can target antibiotic-resistant bacteria ...

Molnupiravir is a pill used to treat COVID-19 in people who are at high risk of developing severe illness. It works by interfering with the ability of SARS‑CoV‑2 (the virus that causes COVID-19) to ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to an expert endocrine ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...

We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...

Here is a look at the best tight end performances from National Tight Ends Day, including George Kittle, Dallas Goedert and ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Q3 2025 Earnings Call Transcript October 27, 2025 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

Big news in the menopause world: The Food and Drug Administration has just approved the drug elinzanetant as a non-hormonal ...